These results indicate that improvements in AD-like inflammation can ameliorate renal dysfunction and dyslipidemia in AD-like model mice, potentially by downregulating the gene expression of the inflammatory mediators S100A8 and S100A9. This evidence concerns the gene S100A8 and metabolic syndrome.